Last reviewed · How we verify

NCT04034680

Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms in Home Care Services

Completed NA Last updated 29 September 2020
What this trial tests

NA trial testing TIME in Dementia in 40 participants. Completed in 30 June 2020.

Timeline
1 February 2019
Primary endpoint
15 June 2020
30 June 2020

Quick facts

Lead sponsorSykehuset Innlandet HF
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment40
Start date1 February 2019
Primary completion15 June 2020
Estimated completion30 June 2020
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Sykehuset Innlandet HF — full company profile →

Who can join

65 and older, any sex, with Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Continuity of care in home care services is necessary to facilitate the assessment and treatment of persons with dementia and cognitive failure. TIME (Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms) is a multi-component intervention with a biopsychosocial approach, based on the theoretical framework of cognitive behavioral therapy and person-centred care. The trial is designed to assess the effects of TIME on Neuropsychiatric symptoms for persons (NPS) with dementia in home care services.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dementia

Currently open trials in the same condition.

Other Sykehuset Innlandet HF trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04034680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing